Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019055 · ClinicalTrials.gov registry record · Phase 1
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03019055 is a Phase 1 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 26 participants.
The verdict
NCT03019055, a Phase 1 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) single chain variable fragment (scFv) coupled to cluster of differentiation CD3ζ (CD3ζ) and co-stimulatory domain 4-1BB (4-1BB) signaling domains in patients with relapsed and/or refractory CD19 or CD20 positive B cell malignancies
Interventions
- BIOLOGICAL CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
- BIOLOGICAL CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)
- BIOLOGICAL CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
- BIOLOGICAL CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2021-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03019055
The ClinicalTrials.gov registry entry for NCT03019055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) is the first listed.
NCT03019055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03019055 about?
NCT03019055 is a clinical study titled "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell". This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) single chain variable fragme...
What is the current status of trial NCT03019055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-10-16. Estimated completion is 2021-08-24.
What interventions are being tested in trial NCT03019055?
The interventions under investigation include: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) (BIOLOGICAL), CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) (BIOLOGICAL), CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) (BIOLOGICAL), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03019055?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.